Showing results (1851-1860 of 3,004) with videos related to
Sort By:
Pageof 301
Neoplasia (New York, N.Y.)|November 9, 2023
Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip systemChris P Miller, Megan Fung, Carla A Jaeger-Ruckstuhl, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 25, 2001
The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behaviorL L Xu, J C Wain, D P Miller, et al.Diabetes Care|September 8, 2000
Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathyS Marsh, F M Nakhoul, K Skorecki, et al.Journal of Medicinal Chemistry|February 1, 1976
Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidinesR H Springer, M K Dimmitt, T Novinson, et al.American Journal of Obstetrics and Gynecology|January 30, 2004
Clinical signs predict 30-month neurodevelopmental outcome after neonatal encephalopathySteven P Miller, Beatrice Latal, Howard Clark, et al.Seminars in Hematology|April 1, 1988
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomasT P Miller, B W Dana, J K Weick, et al.Forensic Science International|September 6, 2005
A novel method of automated skull registration for forensic facial approximationW D Turner, R E B Brown, T P Kelliher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 22, 2019
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic DisordersAshish Gupta, Michael Downey, Ryan Shanley, et al.AJNR. American Journal of Neuroradiology|February 26, 2013
Brain injury patterns in hypoglycemia in neonatal encephalopathyD S T Wong, K J Poskitt, V Chau, et al.Pageof 301